Among all emerging technologies for cancer therapy, one is both highly accurate and efficient: Antibody-Drug Conjugates (ADCs). These missiles are the first such missiles that allow us to kill cancer cells while doingRead More…
The newer cancer treatment is an antibody-drug conjugate (ADC) that combines the immunoprecision of monoclonal antibodies with the cytotoxicity of chemotherapy. It’s a two-step mechanism to ensure therapeutic molecules get to the cancerRead More…
The cure of cancer is not the only goal on the table and the very best are antibody-drug conjugates. These innovative drugs combine monoclonal antibodies with cytotoxic chemotherapies to deliver highly targetedRead More…
Bacterial infections are one of the most serious threats to human health, causing millions of deaths worldwide every year. However, due to the emergence of bacterial resistance, the antibacterial activity of manyRead More…
In a new study, researchers from Yale School of Medicine hide tumor-fighting antibodies from cancer by disguising them in molecules that cancers use to nourish tumor growth, based on a new therapyRead More…
The highly anticipated 115th American Association for Cancer Research (AACR 2024) Annual Meeting opened in San Diego, USA. As the focus of the cancer research community, scientists, clinicians, and cancer researchers fromRead More…
Researchers from the University of Basel in Switzerland published a research paper titled “Selective haematological cancer eradication with preserved haematopoiesis” in the journal Nature. The entire hematopoietic system can be reconstructed byRead More…
The emergence of antibody-drug conjugates (ADCs) as a potential cancer treatment pathway has attracted a great deal of attention. By combining the selective specificity of monoclonal antibodies with the cytotoxicity of drugRead More…
Conditionally activated antibody prodrug conjugate (PDC) Traditional ADCs not only target receptors expressed on tumor cells but also those on certain healthy tissues, leading to inevitable off-tumor toxicity. Probody Drug Conjugates (PDCs)Read More…
Antibody-drug conjugates (ADCs) represent a highly promising approach to cancer treatment, capable of selectively delivering highly cytotoxic payloads to tumors. However, ADCs are currently facing a series of challenges, including resistance, tumorRead More…